Back to News
Market Impact: 0.35
Cullinan's Zipalertinib Plus Chemotherapy Extends PFS By 6 Months In EGFR Ex20+ Lung Cancer
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Cullinan Therapeutics, Taiho Oncology and Taiho Pharmaceutical reported additional Phase 3 REZILIENT3 results for zipalertinib combined with platinum-based chemotherapy as a first-line treatment for advanced EGFR exon 20 insertion-mutated cancer. The update advances clinical validation of the drug candidate, although the provided article text does not include efficacy, safety, or statistical-result details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CGEM0.55
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns
- Microsoft's Big Bets on AI Start to Pay Off